Yiqun Shellman, PhD
Associate Professor, Dermatology
My research interests are cancer and aging of pigment-producing cell (melanocyte). We do both translational and basic research, with the ultimate goals to move some of our research from bench to bedside. We are developing rationale combination treatments for melanoma by targeting the cell death pathway, and exploring the treatment strategies by targeting both the tumor and tumor microenvironment. For more basic studies in the lab, we study how host factors influence antitumor immunity, as well as the molecular and cellular mechanisms for melanocyte stem cell maintenance. These studies are funded by R01, VA merit award, and foundation grants.
Clements CM, Vögeli B, Shellman YG, Henen MA. SAM1 domain of SASH1 harbors distinctive structural heterogeneity. J Struct Biol. 2022 Dec;214(4):107914. PubMed PMID: 36341956
Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, Robinson WA, Tobin RP, McCarter MD, Couts KL, Fujita M, Norris DA, Shellman YG. Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. J Invest Dermatol. 2022 Jul;142(7):1912-1922.e7. PubMed PMID: 34942200
Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, Robinson WA, Tobin RP, McCarter MD, Couts KL, Fujita M, Norris DA, Shellman YG. Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics. J Invest Dermatol. 2021 Dec 20. [Epub ahead of print] PubMed PMID: 34942200
Dart CR, Mukherjee N, Amato CM, Goulding A, MacBeth M, Van Gulick R, Couts KL, Lambert JR, Norris DA, Robinson WA, Shellman YG. A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. Pharmaceuticals (Basel). 2021 Jul 30;14(8). PubMed PMID: 34451846
Mukherjee N, Lambert KA, Norris DA, Shellman YG. Enrichment of Melanoma Stem-Like Cells via Sphere Assays. Methods Mol Biol. 2021;2265:185-199. PubMed PMID: 33704715